Infectious Disease Book


Janus Kinase Inhibitor

Aka: Janus Kinase Inhibitor, Janus Kinase, JAK Inhibitor, Ruxolitinib, Jakafi, Tofacitinib, Xeljanz, Baricitinib, Olumiant, Upadacitinib, Rinvoq
  1. See Also
    1. Biologic Agent
  2. Indications
    1. Rheumatoid Arthritis
    2. Polycythemia Vera
  3. Mechanism
    1. Interferes with Cytokine signalling on receptor binding
  4. Preparations
    1. Ruxolitinib or Jakafi (JAK1 and JAK2 Inhibitor)
      1. Indicated in Rheumatoid Arthritis and Myelofibrosis (including Polycythemia Vera)
    2. Baricitinib or Olumiant (JAK1 and JAK2 inhibitor)
      1. Indicated in Rheumatoid Arthritis
    3. Upadacitinib or Rinvoq (JAK1 inhibitor)
      1. Indicated in Rheumatoid Arthritis
    4. Tofacitinib or Xeljanz (JAK3 Inhibitor)
      1. Indicated in Rheumatoid Arthritis and Psoriasis
      2. Multiple black box warnings
        1. Serious infections
        2. Thrombosis (e.g. Venous Thromboembolism)
        3. Cardiovascular events (e.g. Myocardial Infarction)
        4. Lung Cancer
        5. Increased mortality
      3. References
        1. (2021) Presc Lett 28(4): 22
  5. Adverse Effects
    1. Venous Thromboembolism
    2. Sudden cardiovascular death (associated with Tofacitinib)
    3. Immunosuppression
      1. Tuberculosis reactivation risk
      2. Increased risk of Pneumonia, Shingles
  6. Precautions
    1. Avoid Live Vaccines
  7. References
    1. (2019) Presc Lett 26(10): 58
Medication Costs
xeljanz (on 5/17/2017 at Medicaid.Gov Pharmacy Drug pricing)
XELJANZ 5 MG TABLET $60.77 each
XELJANZ XR 11 MG TABLET $121.33 each
FPNotebook does not benefit financially from showing this medication data or their pharmacy links. This information is provided only to help medical providers and their patients see relative costs. Insurance plans negotiate lower medication prices with suppliers. Prices shown here are out of pocket, non-negotiated rates. See Needy Meds for financial assistance information.

Janus kinase (C0597721)

Definition (CSP) nonEC; family of cytoplasmic protein tyrosine kinases.
Definition (MSH) A family of intracellular tyrosine kinases that participate in the signaling cascade of cytokines by associating with specific CYTOKINE RECEPTORS. They act upon STAT TRANSCRIPTION FACTORS in signaling pathway referred to as the JAK/STAT pathway. The name Janus kinase refers to the fact the proteins have two phosphate-transferring domains.
Concepts Amino Acid, Peptide, or Protein (T116) , Enzyme (T126)
MSH D053612
English JAK Kinases, Janus Kinases, Kinases, JAK, Kinases, Janus, JAK kinase, Janus kinase, Janus Kinases [Chemical/Ingredient]
Portuguese Janus Quinases, Janus-Quinases, Quinases Janus
Spanish Quinasas Janus, Janus-Cinasas, Janus Quinasas, Cinasas Janus, Janus Cinasas, Janus-Quinasas
Italian Chinasi Giano, Jak chinasi
German JAK-Kinasen, Janus-Kinasen
French Janus kinases, Tyrosine-kinases JAK, Tyrosine kinases JAK, JAK Kinases, Kinases JAK, Protéines tyrosine kinases JAK
Finnish Janus-kinaasit
Czech kinasy JAK, Janus kinasy, JAK kinasy
Japanese ヤヌスキナーゼ
Swedish Januskinaser
Polish Kinazy JAK
Derived from the NIH UMLS (Unified Medical Language System)

You are currently viewing the original '\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree